flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Semaglutides Are Poised to Remake Chronic Kidney Disease Care The Effects of Semaglutide on

GLP-1 receptors are expressed throughout the brain, and preclinical evidence indicates that GLP-1 receptor agonists can reduce neuronal damage, improve synaptic function, and counter oxidative stress

Heres how it stacks up: Compared to Other GLP-1 Agonists : Semaglutide is generally more effective at reducing HbA1c and promoting weight loss compared to other drugs in its class

FDA Approvals And Evidence Wegovy (semaglutide): The FDA has approved this for obesity, and trials show strong evidence

instead, the sugar will remain in your bloodstream

Some plans may cover it if prescribed for diabetes, but for weight loss, it may be an out-of-pocket expense